title: High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis.
abstract: To test the carcinostatic effects of ascorbic acid, we challenged the mice of seven experimental groups with 1.7 x 10(-4) mol high dose concentration ascorbic acid after intraperitoneal administrating them with sarcoma S-180 cells. The survival rate was increased by 20% in the group that received high dose concentration ascorbic acid, compared to the control. The highest survival rate was observed in the group in which 1.7 x 10(-4) mol ascorbic acid had been continuously injected before and after the induction of cancer cells, rather than just after the induction of cancer cells. The expression of three angiogenesis-related genes was inhibited by 0.3 times in bFGF, 7 times in VEGF and 4 times in MMP2 of the groups with higher survival rates. Biopsy Results, gene expression studies, and wound healing analysis in vivo and in vitro suggested that the carcinostatic effect induced by high dose concentration ascorbic acid occurred through inhibition of angiogenesis.
authors: Department of Palliative Medicine, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, 137-701, Korea. lymphych@hanmail.net
authors: Chang-Hwan
authors: CH
authors: Yeom
authors: Gunsup
authors: G
authors: Lee
authors: Jin-Hee
authors: JH
authors: Park
authors: Jaelim
authors: J
authors: Yu
authors: Seyeon
authors: S
authors: Park
authors: Sang-Yeop
authors: SY
authors: Yi
authors: Hye Ree
authors: HR
authors: Lee
authors: Young Seon
authors: YS
authors: Hong
authors: Joosung
authors: J
authors: Yang
authors: Sukchan
authors: S
authors: Lee
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D001201:Ascites / Q000188:drug therapy / Q000473:pathology; D001205:Ascorbic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002465:Cell Movement; D004305:Dose-Response Relationship, Drug; D016222:Fibroblast Growth Factor 2 / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D020778:Matrix Metalloproteinase 2 / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D041681:NIH 3T3 Cells; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D012509:Sarcoma / Q000188:drug therapy*; D015996:Survival Rate; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D020778:Matrix Metalloproteinase 2; D001205:Ascorbic Acid